Anticancer effects of HESA-A in patients with metastatic colon cancer.

Mohammadali Mohagheghi, Mehrdad Karimi, Mohsen Naseri, Amrollah Ahmadi

Journal: Integrative cancer therapies 2009;8(1):71-4

PMID: 19147644

Abstract

BACKGROUND

HESA-A is a natural biological compound of herbal-marine origin. The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer.

METHODS

Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied. Patients received HESA-A 50 mg/kg/d orally in 2 to 3 divided doses for 6 months. The patients were assessed at the start and end of the 1st, 2nd, 4th, 8th, 12th, 16th, 20th, and 26th weeks of the study. The Karnofsky Performance Scale questionnaire was completed for each patient.

RESULTS

The mean Karnofsky performance score increased from 33.6 +/- 9.8 to 63.3 +/- 11 after 10 weeks of study. No significant hepatic or hematological adverse effects were seen during the study.

CONCLUSION

It seems that HESA-A is an effective and safe anticancer drug, which can be used in selected patients.

Address: Institute of Cancer Research, Medical Sciences/University of Tehran, Tehran, Iran. [email protected]

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.